Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Merck
Moodys
Mallinckrodt
Boehringer Ingelheim

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Osilodrostat

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Osilodrostat: Sponsors, patents, clinical trial progress

Osilodrostat is an investigational drug.

There have been 6 clinical trials for Osilodrostat. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2016.

The most common disease conditions in clinical trials are Cushing Syndrome, Pituitary ACTH Hypersecretion, and ACTH-Secreting Pituitary Adenoma. The leading clinical trial sponsors are Novartis Pharmaceuticals and [disabled in preview].

There are fifteen US patents protecting this investigational drug and three hundred and fourteen international patents.

Recent Clinical Trials for Osilodrostat
TitleSponsorPhase
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's DiseaseNovartis PharmaceuticalsPhase 2
Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699Novartis PharmaceuticalsPhase 2
Efficacy and Safety Evaluation of Osilodrostat in Cushing's DiseaseNovartis PharmaceuticalsPhase 3

See all Osilodrostat clinical trials

Clinical Trial Summary for Osilodrostat

Top disease conditions for Osilodrostat
Top clinical trial sponsors for Osilodrostat

See all Osilodrostat clinical trials

US Patents for Osilodrostat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Osilodrostat   Start Trial Pharmaceutical dosage forms Novartis AG (Basel, CH)   Start Trial
Osilodrostat   Start Trial Organic compounds Novartis AG (Basel, CH)   Start Trial
Osilodrostat   Start Trial Imidazole derivatives as aldosterone synthase inhibitors Novartis AG (Basel, CH)   Start Trial
Osilodrostat   Start Trial Use of an adrenal hormone-modifying agent Novartis AG (Basel, CH)   Start Trial
Osilodrostat   Start Trial Aldosterone synthase inhibitor Eli Lilly and Company (Indianapolis, IN)   Start Trial
Osilodrostat   Start Trial Organic compounds Novartis AG (Basel, CH)   Start Trial
Osilodrostat   Start Trial Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors Novartis AG (Basel, CH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Osilodrostat

Drugname Country Document Number Estimated Expiration Related US Patent
Osilodrostat Argentina 101116 2034-07-07   Start Trial
Osilodrostat Australia 2015287336 2034-07-07   Start Trial
Osilodrostat Canada 2954393 2034-07-07   Start Trial
Osilodrostat Chile 2017000026 2034-07-07   Start Trial
Osilodrostat China 106470704 2034-07-07   Start Trial
Osilodrostat Denmark 3166596 2034-07-07   Start Trial
Osilodrostat Eurasian Patent Organization 201790140 2034-07-07   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Express Scripts
McKesson
Mallinckrodt
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.